192 related articles for article (PubMed ID: 31132887)
21. Hepatocellular carcinoma: an update on investigational drugs in phase I and II clinical trials.
Noonan A; Pawlik TM
Expert Opin Investig Drugs; 2019 Nov; 28(11):941-949. PubMed ID: 31590579
[No Abstract] [Full Text] [Related]
22. Reply: Heterogeneity of intermediate-stage HCC necessitates personalized management including surgery.
Forner A; Gilabert M; Bruix J; Raoul JL
Nat Rev Clin Oncol; 2015 Jan; 12(1):10. PubMed ID: 25421282
[No Abstract] [Full Text] [Related]
23. Predicting Treatment Response to Intra-arterial Therapies for Hepatocellular Carcinoma with the Use of Supervised Machine Learning-An Artificial Intelligence Concept.
Abajian A; Murali N; Savic LJ; Laage-Gaupp FM; Nezami N; Duncan JS; Schlachter T; Lin M; Geschwind JF; Chapiro J
J Vasc Interv Radiol; 2018 Jun; 29(6):850-857.e1. PubMed ID: 29548875
[TBL] [Abstract][Full Text] [Related]
24. Sorafenib in combination with transarterial chemoembolization for hepatocellular carcinoma: a meta-analysis.
Hu MD; Jia LH; Liu HB; Zhang KH; Guo GH
Eur Rev Med Pharmacol Sci; 2016; 20(1):64-74. PubMed ID: 26813455
[TBL] [Abstract][Full Text] [Related]
25. Transarterial chemoembolization versus transarterial radioembolization in hepatocellular carcinoma: optimization of selecting treatment modality.
Kim DY; Han KH
Hepatol Int; 2016 Nov; 10(6):883-892. PubMed ID: 27126821
[TBL] [Abstract][Full Text] [Related]
26. Intermediate hepatocellular carcinoma: current treatments and future perspectives.
Dufour JF; Bargellini I; De Maria N; De Simone P; Goulis I; Marinho RT
Ann Oncol; 2013 Apr; 24 Suppl 2():ii24-9. PubMed ID: 23715940
[TBL] [Abstract][Full Text] [Related]
27. [Clinical advances in targeted therapy and immunotherapy for hepatocellular carcinoma].
Zhang DZ; Niu JQ
Zhonghua Gan Zang Bing Za Zhi; 2019 Nov; 27(11):834-837. PubMed ID: 31941237
[TBL] [Abstract][Full Text] [Related]
28. Management of hepatocellular carcinoma with transarterial chemoembolization in the era of systemic targeted therapy.
Lencioni R
Crit Rev Oncol Hematol; 2012 Aug; 83(2):216-24. PubMed ID: 22142656
[TBL] [Abstract][Full Text] [Related]
29. Transarterial Chemoembolization and (90)Y Radioembolization for Hepatocellular Carcinoma: Review of Current Applications Beyond Intermediate-Stage Disease.
Fidelman N; Kerlan RK
AJR Am J Roentgenol; 2015 Oct; 205(4):742-52. PubMed ID: 26397322
[TBL] [Abstract][Full Text] [Related]
30. Management of hepatocellular in the United States.
Mokdad AA; Hester CA; Singal AG; Yopp AC
Chin Clin Oncol; 2017 Apr; 6(2):21. PubMed ID: 28482674
[TBL] [Abstract][Full Text] [Related]
31. Novel immunotherapeutic approaches for hepatocellular carcinoma treatment.
Busato D; Mossenta M; Baboci L; Di Cintio F; Toffoli G; Dal Bo M
Expert Rev Clin Pharmacol; 2019 May; 12(5):453-470. PubMed ID: 30907177
[TBL] [Abstract][Full Text] [Related]
32. Imaging assessment of hepatocellular carcinoma response to locoregional and systemic therapy.
Yaghmai V; Besa C; Kim E; Gatlin JL; Siddiqui NA; Taouli B
AJR Am J Roentgenol; 2013 Jul; 201(1):80-96. PubMed ID: 23789661
[TBL] [Abstract][Full Text] [Related]
33. Transarterial chemoembolization using drug eluting beads for the treatment of hepatocellular carcinoma: Now and future.
Woo HY; Heo J
Clin Mol Hepatol; 2015 Dec; 21(4):344-8. PubMed ID: 26770921
[TBL] [Abstract][Full Text] [Related]
34. Design and endpoints of clinical trials in hepatocellular carcinoma.
Llovet JM; Di Bisceglie AM; Bruix J; Kramer BS; Lencioni R; Zhu AX; Sherman M; Schwartz M; Lotze M; Talwalkar J; Gores GJ;
J Natl Cancer Inst; 2008 May; 100(10):698-711. PubMed ID: 18477802
[TBL] [Abstract][Full Text] [Related]
35. Systemic treatment of hepatocellular carcinoma: why so many failures in the development of new drugs?
Brizzi MP; Pignataro D; Tampellini M; Scagliotti GV; Di Maio M
Expert Rev Anticancer Ther; 2016 Oct; 16(10):1053-62. PubMed ID: 27548441
[TBL] [Abstract][Full Text] [Related]
36. Recent developments with immunotherapy for hepatocellular carcinoma.
Waidmann O
Expert Opin Biol Ther; 2018 Aug; 18(8):905-910. PubMed ID: 29995439
[TBL] [Abstract][Full Text] [Related]
37. TACE versus TAE as therapy for hepatocellular carcinoma.
Pleguezuelo M; Marelli L; Misseri M; Germani G; Calvaruso V; Xiruochakis E; Manousou P; Burroughs AK
Expert Rev Anticancer Ther; 2008 Oct; 8(10):1623-41. PubMed ID: 18925854
[TBL] [Abstract][Full Text] [Related]
38. Evolving strategies for the management of intermediate-stage hepatocellular carcinoma: available evidence and expert opinion on the use of transarterial chemoembolization.
Raoul JL; Sangro B; Forner A; Mazzaferro V; Piscaglia F; Bolondi L; Lencioni R
Cancer Treat Rev; 2011 May; 37(3):212-20. PubMed ID: 20724077
[TBL] [Abstract][Full Text] [Related]
39. Transarterial chemoembolization of hepatocellular carcinoma. Agents and drugs: an overview. Part 1.
Giunchedi P; Maestri M; Gavini E; Dionigi P; Rassu G
Expert Opin Drug Deliv; 2013 May; 10(5):679-90. PubMed ID: 23406440
[TBL] [Abstract][Full Text] [Related]
40. Transarterial Chemoembolization within First 3 Months of Sorafenib Initiation Improves Overall Survival in Hepatocellular Carcinoma: A Retrospective, Multi-Institutional Study with Propensity Matching.
Kaplan DE; Mehta R; D'Addeo K; Gade TP; Taddei TH
J Vasc Interv Radiol; 2018 Apr; 29(4):540-549.e4. PubMed ID: 29477619
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]